Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 18 |
| Active Pipeline (Recruiting Now) | 1 (0) |
| Completed vs Stopped Early | 14 / 3 (16.7%) |
| Median Closed Actual Enrollment | 53 participants |
| Physical Hospital Site Disclosure | 31.5% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Explore interactive annual charts and M&A subsidiary rollups in the Aclaris Therapeutics Interactive Dossier, benchmark peers in Immunology, Rheumatology, and Dermatology, or review the Healthcare Price & Patent Cliff Crosswalk.